Eli Lilly and Company $LLY Shares Acquired by J. L. Bainbridge & Co. Inc.

J. L. Bainbridge & Co. Inc. lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 11,690.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 61,782 shares of the company’s stock after buying an additional 61,258 shares during the period. Eli Lilly and Company accounts for approximately 3.9% of J. L. Bainbridge & Co. Inc.’s portfolio, making the stock its 9th largest holding. J. L. Bainbridge & Co. Inc.’s holdings in Eli Lilly and Company were worth $47,139,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Braun Bostich & Associates Inc. lifted its stake in shares of Eli Lilly and Company by 2.5% during the 2nd quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock worth $411,000 after purchasing an additional 13 shares during the period. Rise Advisors LLC increased its stake in Eli Lilly and Company by 1.8% in the second quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after purchasing an additional 13 shares during the last quarter. Occidental Asset Management LLC lifted its position in Eli Lilly and Company by 0.7% during the second quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock worth $1,533,000 after buying an additional 13 shares during the period. New Insight Wealth Advisors lifted its position in Eli Lilly and Company by 3.4% during the second quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after buying an additional 13 shares during the period. Finally, Dash Acquisitions Inc. boosted its stake in Eli Lilly and Company by 2.8% in the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after buying an additional 13 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LLY. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday, December 2nd. BMO Capital Markets set a $1,200.00 price target on shares of Eli Lilly and Company in a research report on Thursday, December 4th. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a report on Monday, December 15th. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Finally, Truist Financial increased their target price on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research report on Wednesday, November 19th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,155.36.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,078.72 on Tuesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99. The company has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.78, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The firm’s fifty day moving average price is $992.14 and its 200 day moving average price is $843.49.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is currently 33.86%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.